Dr. Taddei has built clinical programs at Yale and the VA with a focus on multidisciplinary, integrated care of the patient with liver cancer. In 2009, she developed the VA Connecticut Liver Tumor Board, now a regional tumor board serving VA Medical Centers in Connecticut, Rhode Island, Massachusetts, and Vermont. In 2011, she oversaw the accreditation of the Yale Liver Tumor Board, approved by the Smilow Cancer Hospital at Yale New Haven's Cancer Committee to meet all requirements of accreditation by the American College of Surgeons. She has been funded by the VA National Center for Patient Safety and the VA Office of HIV, Hepatitis and Related Conditions Programs for national implementation of the Coordinated Care Tracking System, a locally developed tool to improve liver cancer detection and comprehensive care. She is co-Principal Investigator of the Veteran's Outcomes and Costs Associated with Liver disease (VOCAL) study group, a national VA research consortium studying outcomes in Veterans with cirrhosis and liver cancer. She is co-Principal Investigator of the VA Clinical Science Research and Development (CSR&D)-funded randomized controlled trial of Statins in Cirrhosis - Reducing Events of Decompensation (SACRED). She is co-Chair of the VA Cooperative Studies Program (CSP)-funded randomized liver cancer screening trial, PREventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM).
She collaborates on several translational projects that seek to understand the biology of liver cancer to inform prognosis and targets for treatment. She mentors trainees in research and considers this one of the most important and gratifying aspects of her career.
Specialized Terms: Clinical, translational, and outcome research on hepatocellular carcinoma
Delivery of Health Care; Digestive System Diseases; Carcinoma, Hepatocellular; Liver Cirrhosis; Translational Research, Biomedical
Health Care Quality, Efficiency; Health Care Management